Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-41-729-7194
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date8/21/2019 (Estimated)
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
When did Auris Medical's stock split? How did Auris Medical's stock split work?
Auris Medical shares reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.
How were Auris Medical's earnings last quarter?
Auris Medical Holding Ltd (NASDAQ:EARS) released its quarterly earnings data on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $1.60. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
2 brokerages have issued 1 year price targets for Auris Medical's shares. Their predictions range from $50.00 to $100.00. On average, they anticipate Auris Medical's stock price to reach $75.00 in the next year. This suggests a possible upside of 2,677.8% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
News stories about EARS stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Auris Medical earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Auris Medical.
Are investors shorting Auris Medical?
Auris Medical saw a decline in short interest in July. As of July 31st, there was short interest totalling 173,600 shares, a decline of 6.2% from the June 30th total of 185,000 shares. Based on an average trading volume of 242,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.7% of the company's shares are short sold. View Auris Medical's Current Options Chain.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Soligenix (SNGX), Cellectar Biosciences (CLRB), Evoke Pharma (EVOK), ANCHIANO THERAP/S (ANCN), Heat Biologics (HTBX), Prana Biotechnology (PRAN), SUMMIT THERAPEU/S (SMMT), Fibrocell Science (FCSC), Intec Pharma (NTEC), Aileron Therapeutics (ALRN), Pulmatrix (PULM), Adial Pharmaceuticals (ADIL), Amarillo Biosciences (AMAR), Edge Therapeutics (EDGE) and Kaya (KAYS).
What other stocks do shareholders of Auris Medical own?
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
- Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
- Colleen A. DeVries, SVP of Cogency Global Inc.
Who are Auris Medical's major shareholders?
Auris Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Morgan Stanley (1.34%), Wedbush Securities Inc. (0.67%) and Jane Street Group LLC (0.58%).
Which institutional investors are selling Auris Medical stock?
EARS stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and Morgan Stanley.
Which institutional investors are buying Auris Medical stock?
EARS stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC.
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $2.70.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $5.05 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
